TNF and inflammatory bowel disease: Therefore, the NORDTREAT trial aims to evaluate whether access to a prognostic protein signature at the initial diagnosis of IBD, coupled with the use of top-down therapy with an anti-TNF agent in high-risk patients identified by the signature, can improve treatment outcomes in this subset of patients.